Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.

Rosalaura V Villarreal GonzálezSandra N Gonzalez-DiazCindy Elizabeth De Lira-QuezadaDavid Gómez-AlmaguerAndres Gómez-De LeónNatalhie Acuña-Ortega

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Severe anaphylaxis has been reported in 1.2% of patients receiving brentuximab vedotin. Patients who are treated by rapid drug desensitization with their first option therapy present a favorable survival rate with better cost-effectiveness in comparison to second-line treatment.

Keyphrases

hodgkin lymphoma
newly diagnosed
ejection fraction
diffuse large b cell lymphoma
prognostic factors
emergency department
drug induced
bone marrow
patient reported outcomes
free survival
patient reported